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Abstract An association between proton pump inhibitor
(PPI) therapy and bacterial gastroenteritis has been sug-
gested as well as contradicted. The aim of this study was to
examine the association between the use of PPIs and
occurrence of bacterial gastroenteritis in the prospective
Rotterdam Study. The Rotterdam Study is a population-
based cohort study among 14,926 subjects aged 45 years
and older with up to 24 years of follow-up. Analyses were
performed with a generalized estimating equations method
in participants who handed-in a diagnostic stool sample.
Furthermore, a nested case–control analysis was performed
using the total cohort as a reference group. A bacterial
microorganism was isolated in 125 samples, whereas 1174
samples were culture negative. In the generalized esti-
mating equations analysis, we found that participants with
a bacterial gastroenteritis were more likely than controls to
be current users of PPIs (adjusted OR 1.94; 95 % CI
1.15–3.25). Different sensitivity analyses did not change
this result. A considerably higher effect was observed
(adjusted OR 6.14; 95 % CI 3.81–9.91), using the total
cohort as a reference in a nested case–control analysis.
Current PPI therapy is associated with an increased risk of
bacterial gastroenteritis. However, by reducing the risk of
selection and information bias in our study design, we
demonstrated that the effect is lower than previously
assumed.
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Introduction
Proton pump inhibitors (PPIs) are among the most fre-
quently prescribed drugs worldwide, but seem to be asso-
ciated with an increased risk of bacterial gastroenteritis [1–
9]. As a result warnings are introduced for people using
PPIs, such as avoiding raw meat consumption and antibi-
otic treatment on demand for travels to the tropics, to
prevent food borne infections. This cohort study was
designed to asses if the magnitude of this risk, warrants
preventive recommendations.
Common indications for PPIs are dyspepsia, peptic ulcer
disease, reflux esophagitis, and Barrett’s oesophagus [10].
PPIs reduce gastric acid production by up to 99 % by
irreversible blocking of H?/K? ATPase of parietal cells in
the stomach [11]. They have a maximal effect within
4 days and the effect may persist up to 3 days after stop-
ping use [12]. Associations between PPIs and infectious
adverse events such as pneumonia, Clostridium difficile-
associated diarrhoea and bacterial gastroenteritis have
often been described [1–9, 13–17]. An increased risk of
gastroenteritis might be explained by the strong reduction
in gastric acid resulting in increased susceptibility to bac-
terial infections. Exogenous bacteria are usually destroyed
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in the stomach when the pH is\3.0. For species such as
Vibrio cholerae and Campylobacter jejuni it has been
shown in vitro that they are very sensitive to pH [18].
However, Salmonella species have been found to respond
to low pH by developing adaptive mechanisms that allow
survival in acid environments [19]. Furthermore, PPIs
change the gut flora, which provides a homeostatic pro-
tection against ingested pathogens [20, 21]. PPIs also
reduce the antibacterial activity of neutrophils which may
facilitate Salmonella and Campylobacter infections [22,
23]. Several case–control studies have shown an increased
risk of acquiring gastrointestinal infections caused by
Campylobacter or Salmonella species in patients using
PPIs [1–8]. In these case–control studies, a relatively high
adjusted odds ratio (aOR) or relative risk was observed,
ranging from 2.9 to 11.7. In one nested case–control study,
in which participants with a gastroenteritis prior to first PPI
prescription were excluded, a considerably lower effect
was observed (aOR 1.6) [9]. It has even been stated that
there is no evidence that PPIs are associated with gas-
trointestinal infections based on outcomes adjusted for pre-
treatment susceptibility to bacterial gastrointestinal infec-
tions and time-dependent confounding factors [24], which
observation suggests that previous case–control studies
have suffered from selection or information bias. There-
fore, we designed a nested case control study within The
Rotterdam Cohort, a prospective cohort study, to examine
the association between the use of PPIs and occurrence of
bacterial gastroenteritis. To minimize the risk of informa-
tion bias we used participants with negative stool samples
as a control group. To test the hypothesis that an incorrect
control group will influence the study results we also




The study was performed in The Rotterdam Study, a
prospective population-based cohort study in 14,926 peo-
ple aged C45 years, from one district (Ommoord) in the
city of Rotterdam, the Netherlands [25]. In short, from
1990 through 1993, 7983 participants were included (co-
hort I). In 2000 an additional 3011 participants who had
become 55 years old or older or who had moved into the
district, were enrolled (cohort II). In 2006 another 3932
participants, aged 45 years and older were included (cohort
III). Follow-up examinations are conducted every
4–5 years. Participants are continuously monitored through
linkage of records from general practitioners.
The Rotterdam Study was approved by the medical
ethics committee according to the Wet Bevolkingsonder-
zoek ERGO (Population Study Act Rotterdam Study)
executed by the Ministry of Health, Welfare and Sports of
the Netherlands. All study participants provided written
informed consent.
Definition of outcome
A case was defined as a community-dwelling non-hospi-
talized individual with a positive stool sample for
Campylobacter, Salmonella, Yersinia or Shigella species.
A control was defined as an individual with a negative stool
sample. Stool sample results were obtained from Star
Medisch Diagnostisch Centrum (Star-MDC), a centre for
medical diagnostics for outpatients in the city of Rotter-
dam. The majority of all laboratory tests, including
microbiology tests, of patients from general practitioners
within the Ommoord district of Rotterdam are performed at
Star-MDC. Of all participants of The Rotterdam Study, of
whom informed consent was obtained for requesting
medical information, positive and negative microbiology
tests between 1999 and April 2013 were obtained. Stool
samples were selected and samples in which parasites were
isolated were excluded. Detection of bacterial enteric
pathogens in stool samples at Star-MDC is performed by
Multiplex polymerase chain reaction (PCR), followed by
culture and microscopy in case of a positive result. Until
December 2010, when PCR was introduced at Star-MDC,
detection of bacterial enteric pathogens was performed by
conventional culture and microscopy only.
Assessment of exposure and covariables
Participants were considered as current user of PPI if the
calendar date of the stool sample fell within a prescription
episode of a PPI. Prescription episodes were calculated by
dividing the total number of supplied pills by the recom-
mended daily number. Additional covariables assessed
were age, sex, cohort, calendar date (year), BMI, household
status, past use of proton pump inhibitors, current or past
use of H2-receptor antagonists, current use of chronic
medication (antidiabetic medication, antihypertensive
medication, or statins), intestinal anti-inflammatory agents,
corticosteroids, immunosuppressant medication, meat
consumption, red meat consumption, chicken consumption,
egg consumption and alcohol consumption (for all dietary
variables: yes/no and gram/days).
BMI and household status was obtained from baseline
characteristics of The Rotterdam Study. Medication use
was obtained through automated linkage with pharmacy
filled prescription data, available from January 1st, 1991
until April 2013. Dietary data were available from 1 week
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food consumption questionnaires obtained at the first visit
of cohort I and cohort III and at the third visit of cohort II.
Multiple imputation (109) of missing dietary data and
BMI was performed using all covariables.
Statistical analyses
Model design
To assess the association between current use of PPIs and
gastrointestinal infections generalized estimating equations
(GEE) was used to adjust for correlation between repeated
measurements in the same participants, using a varying
between-measurement time window [26, 27]. The working
correlation matrix in which the model had the lowest quasi
likelihood under independence model criterion was selec-
ted. The model was adjusted for age and sex and addi-
tionally for covariables changing the point estimate (b) of
current PPI use by more than 10 % or if considered clini-
cally relevant.
Sensitivity analyses
Different sensitivity analyses were performed. To exclude
confounding by indication or protopathic bias we recoded
PPI use started within 14 days before a positive stool
sample as non-use. To take into account that in many
occasions PPIs are not used on a daily basis, and therefore
the actual period of exposure will probably exceed the
period calculated based on the pharmacy data, we also
included use during the past 14 and 30 days as potentially
exposed cases in sensitivity analyses. To exclude con-
founding by contra-indication we censored every partici-
pant at the first case in a sensitivity analysis. Participants
receiving medication from other sources than the phar-
macy, such as nursing home residents, might introduce
information bias. Therefore we did a sensitivity analysis
excluding participants without pharmacy prescriptions
during the last 90 days because nursing home residents do
not obtain medication through a community pharmacy.
Furthermore, we performed a sensitivity analysis for
Campylobacter species and Campylobacter or Salmonella
species only. Different analyses were stratified on sex.
Additional analysis
We also analysed the exposure of PPIs in a nested case–
control analysis to assess the association between PPIs and
gastrointestinal infections in the total population of The
Rotterdam Study. The use of PPIs was used as a time-
varying determinant of exposure as previously described
[28]. To use the total population of The Rotterdam Study
every case (participant with a positive stool sample) was
matched to every other participant alive and eligible at the
same calendar date (day). Each time a case was identified,
exposure in this case was compared with exposure in the
other participants (cases might become controls, and con-
trols might become cases). The model was adjusted for age
and sex and additionally for covariables used in the final
model.
A two-sided p value below 0.05 was considered statis-
tically significant. Statistical analyses were performed
using SPSS version 21.0 (IBM Corp., Somers, NY, USA).
Results
During the study period, 1329 stool cultures of participants
of The Rotterdam Study were identified at Star-MDC. We
excluded 30 stool samples because of isolation of a para-
site, resulting in 1299 stool samples for the study. A bac-
terial microorganism was isolated in 125 samples, whereas
1174 samples were culture negative. In total 105 (84.0 %)
Campylobacter species, 16 (12.8 %) Salmonella species, 3
(2.4 %) Yersinia species and 1 (0.8 %) Shigella sonnei
were isolated. All 125 positive stool samples were col-
lected from 118 different participants and all 1174 negative
stool samples from 903 different participants. The per-
centage of missing data of BMI was 7.6 % and of dietary
data 28.6 %. Characteristics of cases and controls are
shown in Table 1.
Model design
For the generalized estimating equations, the independent
working correlation structure had the best fit. Designing the
final model, past use of H2-receptor antagonists increased
the point estimate (b) of current PPI use, adjusted for age
and sex, by more than 10 %, whereas current use of
chronic medication, all decreased the effect by more than
10 %. We included age, sex, cohort, calendar date, past use
of proton pump inhibitors, past use of H2-receptor antag-
onists, and current use of chronic medication in the final
model (model 2). In the final model we found that partic-
ipants with a bacterial gastroenteritis were more likely than
control participants to be current users of PPIs, with an
aOR of 1.94 (95 % CI 1.15–3.25) (Table 2).
Sensitivity analyses
Different sensitivity analyses did not result in a significant
change of the effect (Table 2). A sensitivity analysis
including use during the past 14 and 30 days resulted in
aORs of 2.14 (95 % CI 1.35–3.38) and 2.28 (95 % CI
1.46–3.55), respectively. Excluding current use of PPIs for
14 days or more, to exclude confounding by indication or
Proton pump inhibitors and gastroenteritis 1059
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protopathic bias, resulted in an aOR of 1.99 (95 % CI
1.19–3.35). Censoring at the first case, to exclude con-
founding by contra-indication, resulted in an aOR of 2.02
(95 % CI 1.19–3.42) and excluding participants without
prescriptions during the last 90 days in an aOR of 1.78
(95 % CI 1.05–3.01). An aOR of 1.93 (95 % CI 1.11–3.36)
and 2.05 (95 % CI 1.20–3.49) was observed in sensitivity
analyses for including only Campylobacter and
Table 1 Baseline characteristics of participants with stool sample
Participants with positive stool sample Participants with negative stool sample
Total 118* 903
Age—year (SD) 65.1 ± 10.3 68.1 ± 12.8
Male sex—no. (%) 49 (41.5) 301 (33.3)
Cohort (%)
I 34 (28.8) 325 (36.0)
II 35 (29.7) 227 (25.1)
III 49 (41.5) 351 (38.9)
Household alone—no. (%) 20 (16.9) 229 (25.4)
BMI (SD) 25.2 ± 4.2 24.5 ± 4.3
Use of proton pump inhibitors—no. (%) 43 (36.4) 242 (26.8)
Current use for 14 days or more 32 (27.1) 152 (16.8)
Including use during past 14 days 50 (42.4) 269 (29.8)
Including use during past 30 days 55 (46.6) 288 (31.9)
[1 Defined daily dose/day 13 (30.2) 76 (31.4)
Past use only 33 (28.0) 289 (32.0)
Medication use—no. (%)
H2-receptor antagonists 3 (2.5) 22 (2.4)
H2-receptor antagonists—past use 37 (31.4) 312 (34.6)
Antidiabetic medication 12 (10.2) 93 (10.3)
Antihypertensive medication 50 (42.4) 316 (35.0)
Statins 27 (22.9) 151 (16.7)
Antidiabetic, antihypertensive medication or statins 55 (46.6) 376 (41.6)
Intestinal anti-inflammatory agents 1 (0.8) 4 (0.4)
Corticosteroids 3 (2.5) 15 (1.7)
Immunosuppressant medication 0 6 (0.7)
Dietary—no. (%)
No meat consumer 2 (2.4) 6 (0.7)
No red meat consumer
Q
2 (2.4) 11 (1.2)
No chicken consumer
Q
15 (18.3) 105 (11.6)
No egg consumer
Q
5 (6.1) 48 (5.3)
Alcohol$ 72 (61.0) 558 (61.8)
Dietary—gram/days (SD)
Meat 110.9 ± 60.4 103.3 ± 54.4
Red meat
Q
91.7 ± 55.0 85.5 ± 50.0
Chicken
Q
17.1 ± 18.1 16.4 ± 16.5
Eggs
Q
15.0 ± 11.1 15.7 ± 12.9
Alcohol$ 13.0 ± 15.7 13.4 ± 15.2
* Out of total 125 positive isolates
 Patients with positive stool sample N = 82, negative stool sample N = 644
 Patients with positive stool sample N = 111, negative stool sample N = 839
Q
Patients with positive stool sample N = 82, negative stool sample N = 646
$ Patients with positive stool sample N = 93, negative stool sample N = 712
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Campylobacter or Salmonella, respectively (Table 2).
After stratifying on sex a difference was observed between
male (aOR 3.28; 95 % CI 1.44–7.49) and female (aOR
1.31; 95 % CI 0.66; 2.60) participants (Table 2).
Additional analysis
In a matched case–control analysis, adjusting for the same
covariables of the final model, but using all other partici-
pants of The Rotterdam Study as control group, a consid-
erably higher aOR of 6.14 (95 % CI 3.81–9.91) was
observed compared to the GEE analysis using negative
stool samples as control group (Table 3).
Discussion
PPIs have been associated with an increased risk of bac-
terial gastroenteritis in previous studies [1–9]. In this
population based cohort study we found that current PPI
therapy was associated with a strongly increased risk of
bacterial gastroenteritis, with an aOR of more than six.
However, this risk decreased to 1.94 after restriction to the
subgroup with stool samples. Therefore, we suspect that
information bias inflated the risks in other population based
studies which have shown an association between PPI
therapy and an increased risk of Campylobacter and Sal-
monella infections before. Although, people using PPIs still
should be careful consuming food which could be
contaminated, such as beef, poultry or processed food, the
risk of gastroenteritis is probably less than previously
assumed.
One of the strengths of our study is that we tried to use a
comparable control group by only using participants with
negative stool samples. In most of the previous population
based studies the magnitude of the effect may have been
overestimated as a result of the use of incomparable control
groups. Typically, case control studies regarding use of
PPIs may suffer from a ‘‘healthy control’’ bias. We further
tried to avoid healthy control bias by correcting for the use
of chronic medication. Some of the previous studies used a
random sample of population registries, or volunteering
friends or relatives of the cases as control group [2, 4–6].
These participants are probably healthier and will therefore
differ considerably from the cases. But also commonly
used strategies, such as using matched controls, obtained
from general practitioner databases, will not prevent
information bias [1]. Studies considering self-limiting
diseases such as gastroenteritis, might select a ‘‘help
seeking’’ and therefore biased population. As a conse-
quence, people using a PPI will be more inclined to consult
medical help in case of gastroenteritis compared to ran-
domly selected controls, even if they are matched.
Residual confounding might also have influenced pre-
vious study results, because dietary pattern, which has been
shown to be the most important risk factors for Campy-
lobacter and Salmonella infections has not been included
in these studies [29, 30]. An association with dietary data
Table 2 Association of use of proton pump inhibitors with bacterial gastrointestinal infections
Number of cases Number in cohort Use of PPI (%) Cases N = 125
OR (95 % CI)
P value
Current use of proton pump inhibitor
Univariate analysis 125 1299 375 (28.9) 1.50 (1.01; 2.23) 0.047
Adjusted analysis—model 1 125 1299 375 (28.9) 1.62 (1.09; 2.43) 0.018
Adjusted analysis—model 2 125 1299 375 (28.9) 1.94 (1.15; 3.25) 0.013
Sensitivity analyses—model 2
Only including current use for 14 days or more 125 1299 242 (18.2) 1.99 (1.19; 3.35) 0.009
Including use during past 14 days 125 1299 422 (32.5) 2.14 (1.35; 3.38) 0.001
Including use during past 30 days 125 1299 453 (34.9) 2.28 (1.46; 3.55) \0.001
Censored at first case 118 1246 353 (28.3) 2.02 (1.19; 3.42) 0.009
Excluding no medication for[90 days 124 1223 375 (30.7) 1.78 (1.05; 3.01) 0.032
Campylobacter only 105 1279 368 (28.8) 1.93 (1.11; 3.36) 0.019
Campylobacter and Salmonella 121 1295 375 (29.0) 2.05 (1.20; 3.49) 0.008
Male only 53 436 131 (30.0) 3.28 (1.44; 7.49) 0.005
Female only 72 863 244 (28.3) 1.31 (0.66; 2.60) 0.45
Generalized estimating equations method, negative stool cultures as control group
Model 1: adjusted for sex, age
Model 2: adjusted for sex, age, cohort, calendar date, past use of proton pump inhibitors, current use of chronic medication, past use of H2-
receptor antagonists
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was not observed in our study. Unfortunately, the number
of missing dietary data in our study was rather high with as
a consequence a large number of imputed data.
Observational studies may always suffer from bias and
residual confounding. We had no data on other important
risk factors for bacterial gastroenteritis, such as foreign
travelling, eating in a restaurant, or contact with animals
[29, 30].
We believe we used a comparable control group using
participants with negative stool samples. However, results
from a test-negative study design may also underestimate
the risk, since a number of the controls with negative stool
cultures may be false-negatives. They can be false-negative
either because of low diagnostic sensitivity against the four
bacterial species (e.g., too little material received, long
transportation time, stool collected many days after onset
of gastroenteritis) or because the patient suffered from
other causes of bacterial gastroenteritis (diarrheagenic
Escherichia coli or Clostridium difficile).
Furthermore, in elderly gastric acid secretion is impaired
compared to younger aged individuals [31]. If gastric acid
secretion is already impaired, PPIs will have a smaller
effect. Therefore, the smaller risk estimate in our study
might be explained by the fact that our population mainly
consisted of elderly, in which gastric acid secretion is
already impaired.
Because Salmonella species are less susceptible to pH,
the association between PPI therapy and gastroenteritis
might be smaller for Salmonella species [19]. Unfortu-
nately, however, the number of Salmonella infections in
this study was too small to draw conclusions on this
association.
During the study period the method of detection of
enteric pathogens changed by the introduction of PCR,
resulting in an increased sensitivity. To correct for an
increased risk of false negative stool samples in the earlier
years of the study, we included calendar date and cohort in
the assessment of model design.
Although male gender has been shown to be an inde-
pendent risk factor for bacterial gastroenteritis, it has not
been shown before that the association between PPI ther-
apy and bacterial gastroenteritis is much higher for males
[32]. We were unable to explain this result by other
covariables. Possibly there are unmeasured (hygiene rela-
ted) behavioural aspects to explain this difference. In
experimental studies a gender difference was observed
between male and female neutrophils. Male neutrophils
show higher responsiveness to stimulation with
lipopolysaccharide and interferon-! [33]. Neutrophils play
an important role in Salmonella and Campylobacter
infections [22, 23]. The harmful effect of PPIs may
therefore be greater for male than for female subjects. Of
course, studies are needed to test this rather speculative
hypothesis.
In conclusion, current PPI therapy was associated with
an increased risk of bacterial gastroenteritis. We demon-
strated that the effect is lower than previously assumed, by
reducing the risk of information bias in our study design.
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Table 3 Association of use of proton pump inhibitors with bacterial gastrointestinal infections
Number of cases Number in cohort Use of PPI (%) Infections N = 125 OR (95 % CI) P value
Total cohort N = 12,515
Current use of proton pump inhibitor
Univariate analysis 125 12,515 11.7* 3.35 (2.31; 4.87) \0.001
Adjusted analysis—model 1 125 12,515 11.7* 4.03 (2.77; 5.87) \0.001
Adjusted analysis—model 2 125 12,515 11.7* 6.14 (3.81; 9.91) \0.001
Male only—model 2 53 5,113 10.2 11.07 (5.51; 22.24) \0.001
Female only—model 2 72 7,402 12.7 3.83 (1.96; 7.47) \0.001
Nested case–control analysis—all other participants of The Rotterdam Study as control group
Model 1: adjusted for sex, age
Model 2: adjusted for sex, age, cohort, calendar date, past use of proton pump inhibitors, current use of chronic medication, past use of H2-
receptor antagonists
* Percentage over 125 strata
 Percentage over 53 strata
 Percentage over 72 strata
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